Die medikamentöse Behandlung der generalisierten Angststörung

Ein Konsensuspapier


Psychopharmakotherapie 2007;14:136–42.

Literatur


Prof. Dr. med. Borwin Bandelow, Dipl.-Psych., Klinik für Psychiatrie und Psychotherapie der Universität Göttingen, v-Siebold-Str. 5, 37075 Göttingen, E-Mail: sekretariat.bandelow@medizin.uni-goettingen.de

Dr. Dr. med. Dipl.-Psych. Reinhard J. Boerner, Klinik für Psychiatrie und Psychotherapie, Christliches Krankenhaus Quakenbrück, Goethestr. 10, 49610 Quakenbrück

O.Univ.- Prof. Dr. Siegfried Kasper, Psychiatrische Universitätsklinik, Abt. Allgemeinpsychiatrie, Allgemeines Krankenhaus Wien, Währinger Gürtel 18–20, 1090 Wien, Österreich

Prof. Dr. Michael Linden, Reha-Klinik Seehof, Lichterfelder Allee 55, 14513 Teltow

Prof. Dr. Hans-Peter Volz, Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin, Schloss Wernec, Balthasar-Neumann-Platz 1, 97440 Wernec

Prof. Dr. phil. habil. Hans-Ulrich Wittchen, Klinische Psychologie und Psychotherapie, Technische Universität Dresden, Chemnitzer Straße 64, 01187 Dresden

Prof. Dr. Hans-Jürgen Möller, Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität München, Nussbaumstraße 7, 80336 München
Übersicht

58. Rickels K, DeMartinis N, Auldembrinke B. A double-blind, placebo-controlled trial of abe-
Bandelow et al. · Medikamentöse Behandlung der GAD
camill und diazepam in the treatment of pa-
69. Schweizer E, Rickels K, Case WG, Green-
blatt DJ. Long-term therapeutic use of benzo-
diazepines. II. Effects of gradual taper. Arch 
70. Rickels K, Schweizer E, Case WG, Greenblatt 
DJ. Long-term therapeutic use of benzo-
diazepines. I. Effects of abrupt discontinuation 
[erratum in Arch Gen Psychiatry 1991;48:51]. Arch 
Gen Psychiatry 1990;47:899–907.
71. Smith DE, Landry MJ. Benzodiazepine de-
pendency: discontinuation: focus on the chem-
ical dependency detoxification setting and 
benzodiazepine-polydrug abuse. J Psychiatr 
72. Bradwejn J. Benzodiazepines for the treat-
ment of panic disorder and generalized anxiety dis-
73. Shader RI, Greenblatt DJ. Use of benzo-
diazepines in anxiety disorders. New Engl J 
74. Livingston MG. Benzodiazepine dependence. 
75. Nelson J, Chouinard G. Guidelines for the 
clinical use of benzodiazepines: pharmacoki-
netics, dependency, rebound and withdrawal. 
Canadian Society for Clinical Pharmacology. 
76. Schweizer E, Rickels K, De Martinis N, Case 
G, et al. The effect of personality on with-
drawal severity and taper outcome in benzo-
diazepine dependent patients. Psychol Med 
77. Rickels K. Benzodiazepines in the treatment 
78. Otto MW, Pollack MH, Sachs GS, Reiter SR, 
et al. Discontinuation of benzodiazepine treat-
ment: efficacy of cognitive-behavioral therapy 
for patients with panic disorder. Am J Psychiat-
ry 1993;150:1485–90.
79. Spiegel DA. Psychological strategies for dis-
continuing benzodiazepine treatment. J Clin 
80. Goddard AW, Brouette T, Alnai A, Jetty P, 
et al. Early coadministration of clonazepam with 
sertraline for panic disorder. Arch Gen Psychiatr 
81. Ferrer M, Hantouche EG, Billardon M. In-
terêt de l’hydroxyzine dans le trouble anx-
iéty généralisé: étude contrôle en double 
avantageux versus placebo. Encéphale 1994;20: 
785–91.
82. Kragh-Sørensen P, Holm P, Fynboe C, 
Schaumburg BM, et al. Bromazepam and 
cloridiazepoxide, and placebo in the treat-
ment of anxiety: a double-blind trial. J Clin 
83. Volz HP, Möller HJ. Opipramol bei Angst-
und Somatisierungsstörungen. Fortschr Neu-
rolog Psychiatr 1998;66(Sonderheft 1/98):S21– 
4.
84. Pollack MH, Roy-Byrne PP, Van Ameringen 
M, Snyder H, et al. The selective GABA re-
uptake inhibitor tiagabine for the treatment of 
85. Naukkarinen H, Raassina R, Penttinien J, 
Ahokas A, et al. Deramciane in the treatment 
of generalized anxiety disorder: A placebo-
controlled, double-blind, dose-finding study. 
23.
86. Volz HP, Kieser M. Kava-kava extract WS 
1490 versus placebo in anxiety disorders – a 
randomized placebo-controlled 25-week out-
patient trial. Pharmacoepychiatry 1997;30: 
1–5.
87. Connor KM, Payne V, Davidson JR. Kava in 
generalized anxiety disorder: three placebo-
controlled trials. Int Clin Psychopharmacol 
88. Boerner RJ, Sommer H, Berger W, Kuhn U,
et al. Kava-Kava Extract WS 1490 versus placebo in anxiety disorder: A placebo-
controlled, double-blind, dose-finding study. 
89. Butler G, Fennell M, Robson P, Gelder M. 
Comparison of behavior therapy and cogni-
tive behavior therapy in the treatment of gen-
eralized anxiety disorder. J Consult Clin 
90. Barlow DH, Rapee RM, Brown TA. Behavio-
rual treatment for generalized anxiety disorder. 
Behav Ther 1992;23:551–70.
et al. Efficacy of a cognitive-behavioral treat-
ment for generalized anxiety disorder: evaluation in a controlled clinical trial. J Con-
92. Dugas MJ, Ladouceur R, Leger E, Freeston 
MH, et al. Group cognitive-behavioral thera-
py for generalized anxiety disorder: treatment 
outcome and long-term follow-up. J Consult 
93. Mohlman J, Gorenstein EE, Kleber M, de 
Jesus M, et al. Standard and enhanced cogni-
tive-behavior therapy for late-life generalized 
anxiety disorder: two pilot investigations. Am 
94. Borkovec TD, Costello E. Efficacy of applied 
relaxation and cognitive-behavioral therapy in 
the treatment of generalized anxiety disorder. 
95. Borkovec TD, Mathews AM, Chambers A, 
Ebrahimis S, et al. The effects of relaxation 
training with cognitive or nondirective thera-
py and the role of relaxation-induced anxiety 
in the treatment of generalized anxiety. J Con-
96. Stanley MA, Beck JK, Novy DM, Arrillar PM, 
et al. Cognitive-behavioral treatment of late-
life generalized anxiety disorder. J Consult 
97. Linden M, Zuberbeg D, Baer T, Franke U, 
et al. Efficacy of cognitive behaviour thera-
py in generalized anxiety disorders. Results of 
a controlled clinical trial (Berlin CBT-GAD 
Psychopharmakotherapie 14. Jahrgang · Heft 4 · 2007 3